Canada: Subsequent Entry Biologics: A New Paradigm

Last Updated: May 13 2013
Article by Melissa A. Binns, John Norman and Patrick S. Smith

Most Read Contributor in Canada, October 2018

There are several biologic drugs approved for use in Canada comprising an estimated 14-16 per cent of the prescription pharmaceutical market. Health Canada defines such drugs as those derived through the metabolic activity of living organisms and are therefore variable and structurally complex. It is this complexity that is introducing a new paradigm of drug development with regards to R&D investment, manufacturing costs and adequate patent protection.

Biologics are typically manufactured from animals, microorganisms, or through the use of animals or microorganisms. They comprise a wide range of therapeutic indications and include products such as vaccines, hormones, enzymes, cytokines and antibodies. Biologic drugs can have a very powerful clinical impact on the management of a wide variety of diseases. For example, the use of biologic medications has revolutionized the treatment of rheumatoid arthritis thereby providing patients with very effective treatment options where few existed in the past.

The complexity of developing a biologic drug as compared to a traditional chemically synthesized drug, requires considerable R&D investment. The U.S. recognizes this investment through extended data protection for biologic drugs. In Canada, while biologic drugs are granted standard data protection, there is no additional recognition for this particular drug class. Since biologics are highly dependent on complex manufacturing processes, follow-on biologics (known in Canada as subsequent entry biologics and biosimilars in the U.S.), pose a number of particular challenges.

Subsequent Entry Biologics (SEBs) are similar, but not identical, to the innovator reference product. These differences raise additional safety and efficacy concerns. For example, SEBs may exhibit a higher immune response in certain patients, thereby leading to unacceptable levels of side effects that may not exist with the innovative product. For these reasons, Health Canada stated that subsequent entry biologics are not generic biologics and it does not support the automatic substitution of an SEB for its reference biologic drug. In other words, SEBs are not interchangeable with the innovator reference product.

SEB applicants must therefore undergo an analogous approval process as innovator biologic drugs by completing a New Drug Submission (NDS). Applications are assessed on a case by-case basis. Although it is preferable for an SEB sponsor to compare its product to a biologic drug authorized in Canada, in certain circumstances, a sponsor may be permitted to seek approval using a non-Canadian reference biologic drug. When this happens, the SEB sponsor is responsible for showing that the non-Canadian reference biologic drug is a suitable proxy for the version of the product approved in Canada.

Comparative studies (both chemical and manufacturing) between the SEB and the innovator product as well as characterization studies are required to establish similarity. According to Health Canada, the extent of the comparability studies depends on the nature of the product, the analytical techniques available to determine product differences and "the relationship between quality attributes and safety and efficacy, based on overall non-clinical and clinical experience." The clinical data required for SEB approval depends on the application, and in theory, may not be as exhaustive as that required of the innovator product. This will depend on the choice of comparable innovator drug, the design of the comparability studies, biological assays and the clinical data that is submitted. For example, Health Canada says an SEB may rely in part on "prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference biologic drug which influences the amount and type of original data required." However, due to the fact that Health Canada considers SEBs to be new stand alone drugs that are not bio-equivalent to their reference product, extensive original testing ought to be required regardless of the initial similarity.

After Health Canada has issued approval for the SEB to be considered a new stand-alone biologic drug, a Notice of Compliance (NOC) and Drug Identification Number (DIN) are issued. SEBs are regulated and monitored in the same fashion as innovator biologics in regards to post-market surveillance. As previous noted, an approved SEB is not considered a bio equivalent of the innovator biologic to Health Canada; however, provinces individually govern whether an SEB can be substituted or interchanged for its reference drug. Consequently, the current system allows provinces to regulate the distribution of SEBs according to their individual healthcare systems.

Members of the medical community have expressed concern over potential SEB interchangeability at the provincial level. In a recent review article published in Clinical Rheumatology, several rheumatologists expressed concerns over the lack of a clear policy from provincial drug plans, stating:

Doctors and patients should remain free to select the most appropriate biologic therapy based on the patients' needs and its history of safe use and clinical response. Decisions to substitute one similar product with another should only be made at a physician's discretion. (Russell et al. Subsequent entry biologic/biosimilars; a viewpoint from Canada, Clin Rheumatol, 26 August 2012)

The review also noted that costs must not override safety and efficacy concerns, and called for strict post-marketing surveillance monitoring of SEBs.

To date, only one SEB has been approved for marketing in Canada. Given recent trends in the U.S. and Europe, combined with the impending expiry of a number of patents covering biologics, it is expected SEB entry in Canada will soon increase dramatically. Biologic drug manufacturers may avail themselves of traditional intellectual property protection such as patent litigation and data protection. SEBs, which make direct or indirect comparison to an innovator reference product, are also subject to the requirements of the Patented Medicines (Notice of Compliance) Regulations ("NOC Regulations"). In fact, 2012 marked the initiation of the first prohibition proceeding under the NOC Regulations involving a biologic drug.

The expected increase of SEBs in the Canadian market over the next several years raises a number of new challenges for biologic drug manufacturers. For example, the validity and infringement of biologic patents, and the treatment of SEBs by provincial formularies and private insurers will all need to be addressed.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions